Skip to main content
. 2007 Aug 1;79(2):93–99. doi: 10.1111/j.1600-0609.2007.00886.x

Figure 3.

Figure 3

Response rates for relapsed or refractory multiple myeloma patients treated with either thalidomide or bortezomib. Response rate was defined using the EBMT criteria or as a confirmed reduction of at least 50% in serum M-protein and by at least 90% for urine M-protein for patients with low baseline serum M-protein.